Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Valproate as an Adjunct to Neuroleptic Medication for the Treatment of Acute Episodes of Mania: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Müller-Oerlinghausen, Bruno, Retzow, Angelika, Henn, Fritz A., Giedke, Henner, Walden, Jörg·2000·Journal of Clinical Psychopharmacology

Abstract

To compare the efficacy of sodium valproate administered as adjunct to neuroleptic medication for patients with acute mania with the efficacy of neuroleptics alone, the authors conducted a 21-day, randomized, double-blind, parallel-group, placebo-controlled trial. The study design closely reflected a clinical psychiatric setting in Europe where patients with acute mania commonly receive neuroleptic medication. In this trial, 136 hospitalized patients met the ICD-10 criteria for acute manic episodes; these patients received a fixed dose of 20 mg/kg of body weight of sodium valproate (Orfiril, Desitin Arzneimittel GmbH, Hamburg, Germany) orally, in addition to basic neuroleptic medication, preferably haloperidol and/or perazine. The primary outcome measure was the mean dose of neuroleptic medication (after conversion into haloperidol-equivalents) for the 21-day study period. Severity of symptoms was measured using the Young Mania Rating Scale (YMRS), the Global Assessment Scale, and the Clinical Global Impression Scale. Intent-to-treat analysis was based on 69 patients treated with valproate and 67 patients who received placebo. Groups were comparable with regard to demographic and clinical baseline data. Premature discontinuations occurred in only 13% of the patients. The mean neuroleptic dose declined continuously in the valproate group, whereas only slight variations were observed in the placebo group; the difference was statistically significant (p = 0.0007) for study weeks 2 and 3. The combination of neuroleptic and valproate proved superior to neuroleptics in attempts to alleviate manic symptoms. The proportion of responders (a 50% improvement rate shown on the YMRS) was higher for the combination with valproate than for the group receiving only neuroleptics (70% vs. 46%; p = 0.005). Adverse events consisted of those known for valproate or neuroleptics; the only adverse event was asthenia, which occurred more frequently with the combination therapy. Valproate represents a useful adjunct medication for the treatment of acute manic symptoms. Valproate is beneficial because it allows the administration of fewer neuroleptic medications and produces improved and quicker remission of manic symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-200004000-00012

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 170

Metadata

Authors
Müller-Oerlinghausen, B., Retzow, A., Henn, F. A., Giedke, H., & Walden, J.
Venue
Journal of Clinical Psychopharmacology
Published
2000-04
Volume
20
Issue
2
Pages
195-203
ISSN
0271-0749 (ISSN-L)
OpenAlex
W159917049
Cited by
170
References
1
FWCI
10.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Valproate as an Adjunct to Neuroleptic Medication for the Treatment of Acute Episodes of Mania: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. https://app.cochat.ai/papers/10.1097/00004714-200004000-00012
The paper
Müller-Oerlinghausen, B., Retzow, A., Henn, F. A., Giedke, H., & Walden, J. (2000). Valproate as an Adjunct to Neuroleptic Medication for the Treatment of Acute Episodes of Mania: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-200004000-00012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.